FDA panel votes in favor of Medicines Co's blood clot preventer

(Reuters) - The Medicines Co's intravenous blood clot preventer can be used in angioplasty procedures, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 9-2 to support the approval of the injection, cangrelor, for use in certain patients undergoing angioplasty, a procedure to widen narrowed or clogged coronary arteries that often includes the use of stents. FDA staff reviewers supported approval of the once-rejected drug in a review published on Monday.



via Health News Headlines - Yahoo News http://ift.tt/1HuinmW